Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23527069 | 1.00 | MAPT (0.58) | MAPTLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL31140790 | 0.88 | NPC1 (0.55) | MAPTLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL31140794 | 0.88 | ALDH1A1 (0.52) | MAPTLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL23527347 | 0.88 | NPC1 (0.55) | MAPTLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL23527203 | 0.88 | ALDH1A1 (0.52) | MAPTLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL23527316 | 0.87 | MAPT (0.59) | MAPTLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL23527277 | 0.82 | GAA (0.61) | MAPTLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL23527345 | 0.81 | PTGES (0.53) | MAPTLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL23527338 | 0.80 | PTGES (0.59) | MAPTLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL23527268 | 0.80 | ALPL (0.64) | MAPTLMNAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600704-B2 | Substituted 1,2,4-triazoles and methods of use | STINGINN LLC (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250163005-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2025-05-22 | — | — | US | disclosed |
| US-12134605-B2 | Substituted 1,2,4-triazoles and methods of use | STINGINN, LLC (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240262796-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2024-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12134605-B2 | Substituted 1,2,4-triazoles and methods of use | STING1, IRF3, CGAS | MAPT 4824/4885LMNA 4430/4885ALDH1A1 3318/4885 |
| US-12600704-B2 | Substituted 1,2,4-triazoles and methods of use | STING1, IRF3, MAVS | MAPT 4720/4885LMNA 1956/4885ALDH1A1 3818/4885 |
| US-20250163005-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STING1, IRF3, CGAS | MAPT 4824/4885LMNA 4430/4885ALDH1A1 3318/4885 |
| US-20240262796-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STING1, IRF3, CGAS | MAPT 4824/4885LMNA 4430/4885ALDH1A1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.